On Tuesday, the European Commission (EC) conditionally approved Merck & Co Inc’s (NYSE:MRK) Welireg (belzutifan), an oral ...

The treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated, localized renal cell ...

The EC has conditionally approved MSD's Welireg as a single agent for the treatment of adults with VHL disease and advanced ...

The European Commission granted approval for von Hippel-Lindau-associated renal cell carcinoma, CNS hemangioblastomas, or pancreatic neuroendocrine tumors.

Merck (MRK) announced that the European Commission has conditionally approved WELIREG, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, ...

Merck’s Welireg receives European approval for two indications: Rahway, New Jersey Wednesday, February 19, 2025, 10:00 Hrs [IST] Merck, known as MSD outside of the United States ...

Rahway: Merck, known as MSD outside of the United States and Canada, has received conditional approval from the European ...

WELIREG was approved in the U.S. in August 2021 for the treatment of adult patients with VHL disease who require therapy for associated RCC, CNS hemangioblastomas or pNET not requiring immediate ...

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory ...